公开(公告)号：US20230203025A1

公开(公告)日：2023-06-29

申请号：US17928468

申请日：2021-05-28

Applicant: Mayo Foundation for Medical Education and Research ,  Sanford Burnham Prebys Medical Discovery Institute

Inventor： John C. Burnett, Jr. ,  Jeson Sangaralingham ,  Siobhan Malany ,  Satyamaheshwar Peddibhotla ,  Paul Mitchell Hershberger ,  Patrick Maloney ,  Edward Hampton Sessions, Jr.

IPC: C07D417/12 ,  A61P9/12

CPC classification number: C07D417/12 ,  A61P9/12

Abstract: In some embodiments, the present disclosure provides a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I), and methods of treating, e.g., metabolic diseases using the compound of Formula (I) are also provided.

公开(公告)号：US11028061B2

公开(公告)日：2021-06-08

申请号：US15748515

申请日：2016-07-27

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Daniel Kelly ,  Richard Vega ,  Hampton Sessions ,  Teresa Leone ,  Byungyong Ahn ,  Satyamaheshwar Peddibhotla

IPC: C07D277/46 ,  A61K31/426 ,  A61K31/5377 ,  A61K31/454 ,  A61K31/496 ,  A61K31/541 ,  C07D417/12 ,  A61K31/4439 ,  C07D417/04 ,  C07D277/82 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04 ,  A61K31/5375 ,  A61K31/428 ,  C07D295/185

Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

公开(公告)号：US11905268B2

公开(公告)日：2024-02-20

申请号：US17267649

申请日：2019-08-12

Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Otto Phanstiel, IV ,  Holly Moots ,  Patrick Maloney ,  Paul Hershberger ,  Satyamaheshwar Peddibhotla

IPC: C07D295/155 ,  A61K45/06 ,  C07D211/46

CPC classification number: C07D295/155 ,  A61K45/06 ,  C07D211/46

Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.

公开(公告)号：US20210300882A1

公开(公告)日：2021-09-30

申请号：US17342187

申请日：2021-06-08

Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Daniel Kelly ,  Richard Vega ,  Hampton Sessions ,  Teresa Leone ,  Byungyong Ahn ,  Satyamaheshwar Peddibhotla

IPC: C07D277/46 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07D417/12 ,  A61K31/5375 ,  A61K31/428 ,  C07D295/185 ,  A61P3/04 ,  A61P3/10 ,  A61K45/06 ,  C07D277/82 ,  C07D417/04

Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

公开(公告)号：US11261164B2

公开(公告)日：2022-03-01

申请号：US16742431

申请日：2020-01-14

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Anthony B. Pinkerton ,  Paul M. Hershberger ,  Satyamaheshwar Peddibhotla ,  Patrick R. Maloney ,  Michael P. Hedrick

IPC: C07D239/94 ,  C07D401/14 ,  C07D401/04 ,  C07D403/12 ,  C07D401/12 ,  C07D403/04 ,  C07D409/14 ,  C07D487/10

Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

公开(公告)号：US10584103B2

公开(公告)日：2020-03-10

申请号：US16140363

申请日：2018-09-24

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Anthony B. Pinkerton ,  Paul M. Hershberger ,  Satyamaheshwar Peddibhotla ,  Patrick R. Maloney ,  Michael P. Hedrick

IPC: C07D239/94 ,  C07D401/14 ,  C07D401/04 ,  C07D403/12 ,  C07D401/12 ,  C07D403/04 ,  C07D409/14 ,  C07D487/10

Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

公开(公告)号：US10118902B2

公开(公告)日：2018-11-06

申请号：US15319329

申请日：2015-06-24

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Anthony B. Pinkerton ,  Paul M. Hershberger ,  Satyamaheshwar Peddibhotla ,  Patrick R. Maloney ,  Michael P. Hedrick

IPC: C07D239/94 ,  C07D403/12 ,  C07D401/14 ,  C07D401/04 ,  C07D487/10 ,  C07D409/14 ,  C07D403/04 ,  C07D401/12

Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

公开(公告)号：US20180222874A1

公开(公告)日：2018-08-09

申请号：US15748515

申请日：2016-07-27

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Daniel Kelly ,  Richard Vega ,  Hampton Sessions ,  Teresa Leone ,  Byungyong Ahn ,  Satyamaheshwar Peddibhotla

IPC: C07D277/46 ,  A61K31/426 ,  A61K31/5377 ,  A61K31/454 ,  A61K31/496 ,  A61K31/541 ,  C07D417/12 ,  A61K31/4439 ,  C07D417/04 ,  C07D277/82 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04

CPC classification number: C07D277/46 ,  A61K31/426 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61P3/04 ,  A61P3/10 ,  C07D277/82 ,  C07D295/185 ,  C07D417/04 ,  C07D417/12

Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.